SCHEMBL10315325

SCHEMBL10315325

c1ccc(-c2ccccc2-c2nnc(-c3ccc(N(c4ccccc4)c4ccc(-c5nc6ccccc6nc5-c5ccc(N(c6ccccc6)c6ccc(-c7nnc(-c8ccccc8-c8ccccc8)o7)cc6)cc5)cc4)cc3)o2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 11/20 0.46
▸ NPC1 O15118 10/20 0.46
▸ SMN1; SMN2 Q16637 8/20 0.46
▸ ALDH1A1 P00352 7/20 0.46
▸ HPGD P15428 6/20 0.46
▸ KDM4E B2RXH2 6/20 0.46
▸ GAA P10253 2/20 0.46
▸ TSHR P16473 3/20 0.44
▸ RXFP1 Q9HBX9 1/20 0.44
▸ ATR Q13535 1/20 0.43
▸ MAPT P10636 4/20 0.42
▸ LMNA P02545 3/20 0.42
▸ NFKB1 P19838 3/20 0.42
▸ NFKB2 Q00653 3/20 0.42
▸ RELA Q04206 3/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ PTGS2 P35354 4/20 0.41
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10315089 1.00 RAB9A (0.46) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL10315125 0.95 L3MBTL1 (0.44) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL4387524 0.92 NPC1 (0.52) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL4245650 0.92 NPC1 (0.52) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL10315092 0.91 NPC1 (0.50) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL10315395 0.91 NPC1 (0.50) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL10315337 0.91 NPC1 (0.50) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL10315124 0.91 NPC1 (0.50) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL10315382 0.91 NPC1 (0.50) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL10315165 0.91 NPC1 (0.50) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2067778-B1 Quinoxaline derivative, and light emitting element, light emitting device and electronic appliance using the same SEMICONDUCTOR ENERGY LAB (JP) 2016-08-17 — — EP disclosed
US-8216696-B2 Quinoxaline derivative, and light emitting element, light emitting device and electronic appliance using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-07-10 — — US disclosed
US-8216696-B2 Quinoxaline derivative, and light emitting element, light emitting device and electronic appliance using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-07-10 — — US disclosed
US-20090153041-A1 Quinoxaline Derivative, and Light Emitting Element, Light Emitting Device and Electronic Appliance Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-18 — — US disclosed
US-20090153041-A1 Quinoxaline Derivative, and Light Emitting Element, Light Emitting Device and Electronic Appliance Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-18 — — US disclosed
EP-2067778-A1 Quinoxaline derivative, and light emitting element, licht emitting device and electronic appliance using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2009-06-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090153041-A1 Quinoxaline Derivative, and Light Emitting Element, Light Emitting Device and Electronic Appliance Using the Same SLC1A2, SLC18A2, SLC18A3 RAB9A 979/4885NPC1 3369/4885SMN1; SMN2 4124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback